Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
17 papers
Recent·Most cited
J. C.-C. Hsu, P. Saenkham, P. Huang, C. P. Octaviani, A. Drelich, B.-H. Peng, C.-T. K. Tseng
This study investigates SARS-CoV-2 neuroinvasion via the trigeminal nerve in AC70 human ACE2 transgenic mice, finding it as an efficient route with altered neuronal function and gene expression but limited tissue pathology.
bioRxiv · Jun 21, 2024Pathology
M. Westberg, Y. Su, X. Zou, P. Huang, A. Rustagi, J. Garhyan, P. B. Patel, D. Fernandez, Y. Wu, L. Ning, A. Beck, M. Karim, C. Hao, P. Saenkham-Huntsinger, V. Tat, , M. Z. Lin
This study designs a SARS-CoV-2 protease inhibitor with improved affinity and reduced mutation sensitivity compared to existing drugs.
bioRxiv · Jul 19, 2023 · PreprintMicrobiology
J. Zhu, S. Jain, J. Sha, H. Batra, N. Ananthaswamy, P. B. Kilgore, E. Hendrix, Y. M. Hosakote, X. Wu, J. P. Olano, A. Kayode, C. L. Galindo, S. Banga, A. Drelich, V. Tat, , V. B. Rao
This paper develops a bacteriophage-based mucosal vaccine that induces strong immune responses and protects against SARS-CoV-2 and its variants without requiring needles or adjuvants.
bioRxiv · Apr 28, 2022Microbiology
H. Ma, C.-T. K. Tseng, H. Zong, Y. Liao, Y. Ke, H. Tang, L. Wang, Z. Wang, Y. He, Y. Chang, S. Wang, A. Drelich, J. Hsu, V. Tat, Y. Yuan, , J. Zhu
This study evaluates the neutralization efficacy of antibodies against SARS-CoV-2 Omicron and other variants, finding that antibody 8G3 maintains broad neutralizing activity while EUA antibodies lose effectiveness.
bioRxiv · Feb 25, 2022 · PreprintCell Biology
H. Ma, Y. Guo, H. Tang, C.-T. Tseng, L. Wang, H. Zong, Z. Wang, Y. He, Y. Chang, S. Wang, H. Huang, Y. Ke, Y. Yuan, M. Wu, Y. Zhang, , J. Zhu
This paper identifies a monoclonal antibody, 2G1, that neutralizes all SARS-CoV-2 variants with high potency and describes its mechanism of action and therapeutic efficacy in animal models.
bioRxiv · Sep 24, 2021Cell Biology
F. Curreli, S. Ahmed, S. M. B. Victor, A. Drelich, S. S. Panda, A. Altieri, A. Kurkin, C.-T. Tseng, C. Hillyer, A. Debnath
The paper identifies potent small molecules that inhibit multiple coronaviruses, including SARS-CoV-2 variants, with high selectivity and in vivo efficacy.
bioRxiv · Sep 3, 2021Pharmacology & Toxicology
M. A. Barry, H. Mudrick, E. McGlinch, B. Parrett, J. Hemsath, M. Barry, J. Rubin, C. Uzendu, M. Hansen, C. Erskine, V. VanKeulen, A. Drelich, C.-T. K. Tseng, C. S. Massey, M. Fida, , G. Olivier
This study compares mucosal and intramuscular immunization with replication-defective and replicating single-cycle adenovirus vaccines against SARS-CoV-2, showing that replicating vaccines generate stronger antibody responses.
bioRxiv · Apr 20, 2021 · PreprintImmunology
V. B. Rao, J. Zhu, N. Ananthaswamy, S. Jain, H. Batra, W.-C. Tang, D. A. Lewry, M. L. Richards, S. A. David, P. B. Kilgore, J. Sha, A. Drelich, C.-T. Tseng, A. K. Chopra
This paper develops a CRISPR-engineered bacteriophage T4 nanoparticle platform to create multiplex SARS-CoV-2 vaccine candidates, showing potent immune responses and protection in animal models.
bioRxiv · Jan 19, 2021Microbiology
A. Ashhurst, A. Tang, P. Fajtova, M. Yoon, A. Aggarwal, A. Stoye, M. Larance, L. Beretta, A. Drelich, D. Skinner, L. Li, T. Meek, J. McKerrow, V. Hook, C.-T. Tseng, , R. J. Payne
bioRxiv · Dec 23, 2020 · PreprintBiochemistry
G. Ye, J. Gallant, C. Massey, K. Shi, W. Tai, J. Zheng, A. Odle, M. Vickers, J. Shang, Y. Wan, A. Drelich, K. Kempaiah, V. Tat, S. Perlman, L. Du, , F. Li
This paper develops a potent, low-cost nanobody therapeutic, Nanosota-1C-Fc, that effectively blocks SARS-CoV-2 infection in vitro and in vivo with high affinity and stability.
bioRxiv · Nov 17, 2020Microbiology
Y. Liu, C. Zhou, Z. Su, Q. Chang, Y. Qiu, J. Bei, A. Gaitas, J. Xiao, A. Drelich, K. Khanipov, Y. Jin, G. Golovko, T. Berelli Saito, B. Gong
This study investigates the role of Rickettsia-infected endothelial cell-derived exosomes in causing barrier dysfunction in brain microvascular endothelial cells, identifying miR-23a and miR-30b as key regulators.
bioRxiv · Nov 16, 2020Microbiology
D. Mellott, C.-T. Tseng, A. Drelich, P. Fajtova, B. C. Chenna, D. Kostomiris, J. C. Hsu, J. Zhu, Z. Taylor, V. Tat, A. Katzfuss, L. Li, M. A. Giardini, D. Skinner, K. Hirata, , J. H. McKerrow
This paper shows that K777, a cysteine protease inhibitor, blocks SARS-CoV-2 infection by inhibiting host cathepsin L, which is required for spike protein processing, with nanomolar efficacy in several cell lines.
bioRxiv · Oct 23, 2020 · PreprintBiochemistry
F. Curreli, S. M. B. Victor, S. Ahmed, A. Drelich, X. Tong, C.-T. K. Tseng, C. D. Hillyer, A. K. Debnath
This study designs stapled peptides based on the ACE2 helix to inhibit SARS-CoV-2 infection, showing potent antiviral activity with no cytotoxicity.
bioRxiv · Aug 25, 2020Pharmacology & Toxicology
E. C. Vatansever, K. S. Yang, K. C. Kratch, A. Drelich, C.-C. Cho, D. M. Mellott, S. Xu, C.-T. K. Tseng, W. R. Liu
This study identifies bepridil as a potent inhibitor of SARS-CoV-2 MPro and virus entry, showing efficacy in vitro at low concentrations.
bioRxiv · May 23, 2020Pharmacology & Toxicology
W. Li, A. Drelich, D. R. Martinez, L. E. Gralinski, C. Chen, Z. Sun, A. Schäfer, S. R. Leist, X. Liu, D. V. Zhelev, L. Zhang, E. L. Peterson, A. Conard, J. W. Mellors, C.-T. Tseng, , D. S. Dimitrov
This study rapidly identifies a potent human monoclonal antibody against SARS-CoV-2 that neutralizes the virus in animal models and shows promise for therapeutic use.
bioRxiv · May 13, 2020 · PreprintMicrobiology
Z. Su, Q. Chang, A. Drelich, T. Shelite, B. Judy, Y. Liu, J. Xiao, C. Zhou, X. He, T. Saito, S. Tang, L. Soong, M. Wakamiya, X. Fang, A. Bukreyev, , B. Gong
This study shows that ANXA2 depletion increases CMHs in rickettsia and Ebola virus infections by disrupting BBB tight junctions.
bioRxiv · Dec 2, 2019Pathology
X. He, A. Drelich, Q. Chang, D. Gong, Y. Zhou, Y. Qu, S. Yu, Y. Yang, J. Qian, Y. Qiu, S.-J. Tang, A. Gaitas, T. Ksiazek, Z. Xu, M. Wakamiya, , B. Gong
This study shows that EPAC1 promotes ANXA2 translocation to endothelial cell surfaces, enhancing plasminogen to plasmin conversion and fibrinolysis.
bioRxiv · Oct 1, 2017Cell Biology